Abstract Title:

Antiproliferative and apoptosis-inducing activity of nobiletin against three subtypes of human breast cancer cell lines.

Abstract Source:

Anticancer Res. 2014 Apr ;34(4):1785-92. PMID: 24692711

Abstract Author(s):

Chen Chen, Misaki Ono, Mikako Takeshima, Shuji Nakano

Article Affiliation:

Chen Chen


UNLABELLED: Although nobiletin has a potent antitumor activity against several types of human cancers, its inhibitory effects and possible mechanisms of action on breast cancer cells with different hormone receptor and HER2 status remains unknown.

MATERIALS AND METHODS: Using hormone receptor-positive MCF-7, HER2-positive SK-BR-3, and triple-negative MDA-MB-468 cell lines, we investigated the antitumor mechanisms of nobiletin.

RESULTS: Nobiletin exhibited dose- and time-dependent antitumor activity against these different subtypes of cell lines, with the greatest inhibition observed against the MDA-MB-468 cell line. Nobiletin induced cell-cycle arrest at the G0/G1 phase by suppressing ERK1/2 activity, with concomitant cyclin-D1 suppression and p21 up-regulation. Nobiletin induced apoptotic cell death by reducing Bcl-xL expression, without affecting Bax levels, and inhibited the activity of AKT and downstream mTOR in MDA-MB-468 cells, but not in other cell lines.

CONCLUSION: The predominant anticancer activity of nobiletin in MDA-MB-468 cells suggests a potential role of nobiletin for the prevention of triple-negative breast cancer.

Print Options

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2020 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.